Article Text

Download PDFPDF
Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review
  1. Michael C Steiner1,
  2. Ronenn Roubenoff2,
  3. Ruth Tal-Singer3,
  4. Michael I Polkey4
  1. 1Institute for Lung Health, Department of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK
  2. 2Musculoskeletal Translational Medicine, Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA
  3. 3GlaxoSmithKline, Respiratory Therapy Area Unit, King of Prussia, Pennsylvania, USA
  4. 4NIHR Respiratory Biomedical Unit at the Royal Brompton Hospital and National Heart & Lung Institute, London, UK
  1. Correspondence to Dr Michael C Steiner, Institute for Lung Health, Department of Respiratory Medicine, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Groby Road, Leicester LE3 9QP, UK; michael.steiner{at}uhl-tr.nhs.uk

Abstract

Skeletal muscle dysfunction is a prevalent and clinically important systemic manifestation of chronic obstructive pulmonary disease (COPD) that predicts morbidity and mortality. Skeletal muscle retains its plasticity in response to anabolic stimuli such as exercise in COPD and is therefore a promising target for novel pharmacological therapies aimed at reducing disability and healthcare utilisation and improving mortality. In this article, we outline the steps the academic and pharmaceutical communities need to undertake for such therapeutic advances to be realised.

  • COPD mechanisms
  • exercise
  • pulmonary rehabilitation
  • COPD pharmacology
  • cystic fibrosis
  • cytokine biology
  • exhaled airway markers
  • innate immunity
  • neutrophil biology
  • viral infection
  • non invasive ventilation
  • respiratory muscles

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; externally peer reviewed.